TherapeuticsMD, Inc.
TXMD
$1.10
$0.01991.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 142.24% | -41.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 142.24% | -41.08% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 142.24% | -41.08% | |||
| SG&A Expenses | 8.70% | 22.98% | |||
| Depreciation & Amortization | 1.05% | -5.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.08% | 20.12% | |||
| Operating Income | 59.26% | -150.96% | |||
| Income Before Tax | 181.59% | -904.82% | |||
| Income Tax Expenses | -- | -3.23% | |||
| Earnings from Continuing Operations | 185.69% | -657.89% | |||
| Earnings from Discontinued Operations | 135.29% | -112.32% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 184.38% | -359.13% | |||
| EBIT | 59.26% | -150.96% | |||
| EBITDA | 67.59% | -224.53% | |||
| EPS Basic | 184.25% | -357.99% | |||
| Normalized Basic EPS | 193.63% | 50.08% | |||
| EPS Diluted | 177.40% | -380.82% | |||
| Normalized Diluted EPS | 193.63% | 50.08% | |||
| Average Basic Shares Outstanding | 0.19% | 0.17% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||